Clik here to view.
A Decade of Innovation and Growth: Cook Korea 10th Anniversary
SEOUL, South Korea Cook Medical celebrated its 10-year anniversary with a special event that marked a major milestone – a decade of successful customer service, innovation and employee development....
View ArticleClik here to view.
HiFiBiO Therapeutics Establishes World-Class Scientific Advisory Board
CAMBRIDGE, Mass. & SHANGHAI & PARIS HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, today announced...
View ArticleClik here to view.
拓臻生物宣布其非酒精性脂肪性肝炎(NASH)候选药物TERN-101获得美国FDA快速通道认证
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals 拓臻生物一家专注非酒精性脂肪性肝炎（NASH）和癌症创新疗法研发的全球生物制药公司，今天宣布其候选药物法尼醇X受体（FXR）激动剂TERN-101已获得美国食品和药物管理局（FDA）针对治疗NASH适应症的快速通道认证。 拓臻生物首席医学官Erin...
View ArticleClik here to view.
Terns Pharmaceuticals Receives Fast Track Designation From the FDA for...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014...
WALTHAM, Mass. Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the presentation of...
View ArticleClik here to view.
EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab (development code:...
View ArticleClik here to view.
Terns Pharmaceuticals、NASH治療を目的とするFXR作動薬TERN-101に対するファストトラック指定をFDAより取得
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleAVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here:...
View ArticleClik here to view.
武田薬品：2019年度第2四半期の堅調な連結業績と通期業績予想の上方修正について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502) (NYSE:TAK)： 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20191030006223/ja/ 2019年度上期の実質的な売上収益は対前年同期△0.2％（Pro-forma2）...
View ArticleClik here to view.
All India Institute of Medical Sciences Finalizes the Biolog-id Transfusion®...
NEW DELHI Concluding the preliminary phase of a relationship started almost 18 months ago, AIIMS (New Delhi, India) and Biolog-id (Paris, France) have successfully completed a multi-phases...
View ArticleClik here to view.
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug...
NASHVILLE, Tenn. & TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today...
View ArticleClik here to view.
Quality Electrodynamics (QED) Sells Majority Ownership Interest to Canon Inc.
MAYFIELD VILLAGE, Ohio Quality Electrodynamics, LLC (QED), headquartered in Mayfield Village, Ohio, announced today the sale of 70% of its ownership interest to Canon Inc. (Canon) headquartered in...
View ArticleClik here to view.
Clik here to view.
玫琳凯基金会向Baylor Scott & White捐款10万美元以支持三阴性乳腺癌研究
达拉斯 (美国商业资讯)–玫琳凯基金会(The Mary Kay FoundationSM)引领根除女性癌症的使命已有数十载，该基金会最近向Baylor Scott & White达拉斯基金会捐款10万美元，以资助TEXAS Oncology的乳腺癌医生、贝勒大学医疗中心乳腺癌研究“颂扬女性”(Celebrating Women)主任Joyce...
View ArticleClik here to view.
玫琳凯基金会向癌症研究和家暴庇护所提供310万美元资助
达拉斯 (美国商业资讯)–玫琳凯基金会(The Mary Kay FoundationSM)最近向全美癌症研究和家庭暴力庇护所提供300多万美元资助。玫琳凯基金会创立于1996年，首要目的是消除那些影响女性的癌症。2000年，基金会将终止家庭暴力纳入其服务宗旨。...
View ArticleClik here to view.
Octapharma宣布发表fibryga®用于治疗心脏手术患者获得性纤维蛋白原缺乏的数据
瑞士拉亨 (美国商业资讯)–Octapharma宣布发表新的数据，数据显示，纤维蛋白原浓缩物fibryga®是用于心脏手术期间重度出血患者的冷凝蛋白的有效代用品。该数据近期发表于《美国医学会杂志》(JAMA)1。...
View ArticleClik here to view.
Epizyme Establishes Agreements for Up to $270 Million in Funding to Support...
CAMBRIDGE, Mass. Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced funding agreements with Royalty Pharma and its affiliate...
View ArticleClik here to view.
Harbour BioMed Announces Initiation of First-in-human Study of...
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SHANGHAI Harbour BioMed (HBM) today announced the start of the first clinical trial of its next-generation fully human anti-CTLA-4 antibody...
View ArticleClik here to view.
Kraig Biocraft Laboratories Completes Rearing of First Production Batch of...
ANN ARBOR, Mich. Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its operations team at its Vietnamese...
View Article